CN106267159A - A kind of oral care composition - Google Patents
A kind of oral care composition Download PDFInfo
- Publication number
- CN106267159A CN106267159A CN201610814300.2A CN201610814300A CN106267159A CN 106267159 A CN106267159 A CN 106267159A CN 201610814300 A CN201610814300 A CN 201610814300A CN 106267159 A CN106267159 A CN 106267159A
- Authority
- CN
- China
- Prior art keywords
- growth factor
- restructuring
- cell growth
- liposome
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a kind of oral care composition, be made up of heterogeneous unilamelar liposome parcel restructuring epithelical cell growth factor and tetrahydropyrimidine mixing water gel.Liposome therein accounts for 80% the 99.8% of composition weight, and mean diameter is between 600 1600nm；Restructuring epithelical cell growth factor therein accounts for the 0.1 10.0% of composition weight, and its concentration is 100 2000mg/kg, and molecular weight is 5900 6500Da, and sedimentation coefficient is 1.20 1.30S, and isoelectric point, IP is pH4.5 4.9, for lyophilized powder；Described tetrahydropyrimidine accounts for the 0.1 10.0% of composition quality ratio, and purity is 99% 100%, for powdery.The present invention has the effect of Synergistic to oral inflammation, ulcer prevention.
Description
Technical field
The present invention relates to field of oral care, be specifically related to heterogeneous unilamelar liposome parcel restructuring epithelical cell growth factor
With tetrahydropyrimidine mixing water gel composition.
Background technology
Epithelical cell growth factor (Epidermai Growth Factor), is called for short EGF；It is that one is widely present in people
Skin Cell, body fluid, kidney and cerebral tissue in the biologically active polypeptide being made up of 53 aminoacid, be that one has physiology
The bioactive substance of function, has the strongest biological effect.In human body, the epithelical cell growth factor of denier is with regard to energy
Play the biggest biological action, propagation and the growth of skin tissue cell can be promoted, make newborn young cell replace rapidly
Aging and dead cell.It is periodically Skin Cell supplementary table skin cell growth factor, it is possible to persistently promote the synthesis of cell, protects
Hold the metabolism that epidermis cell is vigorous, also have and promote skin and mucosa wound healing, anti-inflammatory analgetic, prevent and treat effect of ulcer.
But epithelical cell growth factor content in human body cell and tissue is extremely low, limited source is expensive.
Someone passes through escherichia coli, bacillus brevis, yeast gene recombination technology and zooblast, plants the most successively
Thing cell, alga cells In vitro culture, it is achieved that restructuring epithelical cell growth factor (Recombinant epidermal
Growth factor, rhEGF) mass production.But in actual use, the stability of restructuring epithelical cell growth factor is subject to
To the impact of the factors such as temperature, pH value, protease, additive (antibacterial, antioxidant etc.), activity is made to be substantially reduced.As for
Ulcerative conditions, the enzyme of wound face can be degraded restructuring epithelical cell growth factor, needs to add enzyme inhibitor.
Tetrahydropyrimidine (Isosorbide-5-Nitrae, 5,6-tetrahydro-2-methyl-4-pyrimidinecarboxylic acid) is N-
A kind of pyrimidine derivatives that acetylizad DAB is formed by intramolecular dehydration, is the master in most of Halophilic Bacterium
Want compatible solute.Tetrahydropyrimidine can stablize the biomacromolecule such as the hydration layer of native protein, protective enzyme, DNA, RNA and
Membrane structure, helps the characteristic of the various non-specific environment such as cell resistance high salt, high temperature, low moisture, freezing and radiation.
Tetrahydropyrimidine is compounded as a kind of protective agent and restructuring epithelical cell growth factor, on the one hand can protect restructuring
Epithelical cell growth factor is not affected by factors such as temperature, pH value, protease, additives (antibacterial, antioxidant etc.)；Another
Aspect can protect the regenerative cell at inflammation, ulcer, wound surface.
Summary of the invention uses liposome can also improve the stability of biological preparation simultaneously.Liposome is in cosmetics
Application comparison many, mainly include two aspects: one, liposome avoids bioactive substance mutual as the carrier of functional components
Effect or generation biodegradation；Two, the phospholipid in liposome membrane and unsaturated fatty acid itself have good moisturizing and skin protection
Effect.Liposome particularly its lipoid similar to skin composition, the liposome formed such as sphingomyelin and skin keratin
Layer lipid has high similarity, can increase the medicine accumulation at local skin, strengthens skin targeting, and can sustained release medicine
Thing；There is the effect strengthened in medicine entrance horny layer and epidermis lipoid.
It is substantially the topical for skin that liposome is applied in cosmetics: designing fat with skin for targeting moiety
During plastid, retain in skin with should making medicine maximum, enter blood circulation as little as possible, i.e. effectiveness composition acts on skin
The horny layer on skin surface or enter epidermis or corium.I.e. liposome and other functional components transdermal penetration to be realized in cosmetics
And avoid entering blood circulation through skin, cause toxic and side effects. simultaneously.At present, the research of liposome percutaneous dosing shows: fat
The plastid particle diameter liposome more than 1000nm is mainly stranded in horny layer；The liposome of 600nm-1000nm can penetrate into epidermis
Layer and skin corium；Liposome less than 200nm then can be directly entered systemic circulatory system, causes toxic and side effects.Further contemplate simultaneously
To different dosage forms, therefore, we select preparation method time based on the method preparing single chamber multiphasic liposomes.
Summary of the invention
It is an object of the invention to provide a kind of oral care composition, by tetrahydropyrimidine and restructuring epidermal growth because of
Son is compounding, and the most in addition liposome improves all drawbacks being used alone restructuring epithelical cell growth factor, the most right
Oral inflammation, ulcer prevention have the effect of Synergistic.
The above-mentioned purpose of the present invention is achieved by following scheme:
A kind of oral care composition, described oral care composition is thin by heterogeneous unilamelar liposome parcel restructuring epidermis
The intracellular growth factor and tetrahydropyrimidine mixing water-setting agent are constituted.
Described liposome accounts for the 80%-99.8% of composition weight, is made up of a phosphate and a quaternary ammonium salt base
Hydrophilic radical and the lipophilic group of two longer alkyl composition, mean diameter is between 600-1600nm.Wherein fat
Plastid is including at least one or more compositions in lecithin, cholesterol, ceramide, sphingomyelins.
Described restructuring epithelical cell growth factor accounts for the 0.1-10.0% of composition weight, and its concentration is 100-
2000mg/kg, molecular weight is 5900-6500Da, and sedimentation coefficient is 1.20-1.30S, and isoelectric point, IP is pH4.5-4.9, for lyophilized powder
Shape.
Described tetrahydropyrimidine accounts for the 0.1-10.0% of composition quality ratio, and purity is 99%-100%, for powdery.
Compared with prior art, the method have the advantages that:
1, tetrahydropyrimidine can protect restructuring epithelical cell growth factor, (is not pressed down by temperature, pH value, protease, additive
Microbial inoculum, antioxidant etc.) etc. the impact of factor and reduce activity, it is provided that the stability of use.
2, tetrahydropyrimidine itself has protective effect to regenerative cell, and restructuring epithelical cell growth factor is to stomatitis
Disease, ulcer prevention have the effect of Synergistic.Such as make ulcer surface regenerative cell no longer be invaded and harassed by the secondary of antibacterial, accelerate to increase
Grow.
3, the oral care implement compositions that the present invention provides uses single chamber multiphasic liposomes parcel form, and liposome is to two
Plant biological preparation and protection is provided, meet the requirement of the different conditions such as water preparation and Emulsion, improve the stability of compositions simultaneously.
Detailed description of the invention
Restructuring epithelical cell growth factor in the present invention can be by escherichia coli, bacillus brevis, yeast gene recombinaton
Technology and zooblast, plant cell, alga cells In vitro culture obtain, and preparation method is by disclosed in prior art.It is dense
Degree is 100-2000mg/kg, for lyophilized powder.
Tetrahydropyrimidine in the present invention can be obtained by methods such as oxaloacetic acid or engineering strain biosynthesiss, preparation
Method is by disclosed in prior art.Purity is 99%-100%, for powdery.
The liposome of the present invention can be made up of one or more in lecithin, cholesterol, ceramide, sphingomyelins.
Can ensure that heat-resistant superoxide dismutase and the stability of epithelical cell growth factor, biocompatibility, Transdermal absorption are eased up
Release controlled-release effect.Liposome can be prepared by with dehydration rehydration method or prefabricated liposome method.This preparation method is by prior art
Disclosed, and the envelop rate additive method that compares is the highest, reaches 65-80%
The water-setting agent of the present invention is made up of wetting agent and thickening agent, wetting agent preferably glycerine, Polyethylene Glycol, propylene glycol, mountain
Pears (sugared) alcohol one or more；The preferred gelatin of thickening agent, Polyethylene Glycol, sodium carboxymethyl cellulose, carbomer one or more.
Most preferred embodiment (oral care composition gel)
Restructuring epithelical cell growth factor, tetrahydropyrimidine, lecithin, cholesterol, sheath phosphorus in above-mentioned oral care composition
Fat, ceramide, glycerol, Macrogol 4000, gelatin, sodium carboxymethyl cellulose, Carbopol, triethanolamine are commercially available
Sterling.Wherein restructuring epithelical cell growth factor concentration is 1100mg/kg, for lyophilized powder；Tetrahydropyrimidine purity is 99.5%, for
Powdery.
The preparation method of most preferred embodiment:
Will restructuring epithelical cell growth factor, tetrahydropyrimidine, gel (Macrogol 4000, gelatin, carboxymethyl cellulose
Sodium, Carbopol) add in glycerol under room temperature and stir (carbomer system needing after 30 minutes add triethanolamine neutralize) and formed
Clear gel, adds set aside for use after water continues to stir 2 hours.
Above-mentioned hydrogel adhesive, lecithin, cholesterol, ceramide, sphingomyelins are dissolved by organic solvent, makes lipid
Solution.
By fluid bed by proppant middle with being suspended in fluid bed for above-mentioned liposome solutions Direct spraying, volatilization has
Machine solvent, obtains restructuring epithelical cell growth factor/tetrahydropyrimidine hydrogel liposome.
Organic solvent described in the present embodiment includes dichloromethane, chloroform, ether and ethanol.
Proppant described in the present embodiment is selected from mannitol, glucose, sorbitol, sucrose, lactose, trehalose, sodium chloride
With the one in polyvinylpyrrolidone.
The stability of most preferred embodiment:
Most preferred embodiment D is placed in airtight centrifuge tube, preserves 6 months respectively at 60 DEG C, 37 DEG C, room temperature and-18 DEG C, fixed
Time detection the outward appearance of gel, dehydration, acid-base value and restructuring epithelical cell growth factor content.Result shows, gel is almost
Do not have physical appearance change, pH value the most unchanged.Radio immunoassay (RIA) method is used to measure restructuring epidermis in gel thin
The concentration of the intracellular growth factor and activity, result display density and preparation time identical, activity for preparation time 97%.
The clinical effectiveness of most preferred embodiment:
Case selection
Eligibility 70 example (male 40 examples, female 30 example), wherein test group 35 example, matched group 35 example.Man in test group 30 example
20 examples, female 15 example, year mean age (31.26 ± 8.45), minor aphtha 17 example, ulcer 13 example, herpetic stomatitis 5 example；Comparison
Organize male 20 examples in 30 examples, female 15 example, year mean age (30.22 ± 10.78), minor aphtha 15 example, ulcer 17 example, herpetic mouth
Scorching 3 examples.
Test method
This test takes random parallel check experiment to design.Test group most preferred embodiment D gel, with front gargling, uses
It is appropriate that aseptic cotton carrier dips gel, and uniform application is in affected part, and thickness about 2mm, using to ulcer healing or 2 weeks is that treatment is whole
Point；Matched group equivalent is recombinated merely epithelical cell growth factor gel, and usage, consumption are identical with test group with the course for the treatment of.Phase
Between disable other treatment ulcer medicine.
Observation index
Check the position of ulcer, number, size, the degree of depth, form and surrounding mucosa situation.With the healing of all ulcer wound surfaces it is
Index judges healing time.
Result
Though test group healing is the shortest compared with matched group, healing number of cases substantially increases.
In this test, all do not find the most not quantitative response, have no that local irritation is reacted.
Claims (1)
1. an oral care composition, it is characterised in that: described oral care composition is heterogeneous unilamelar liposome parcel
Restructuring epithelical cell growth factor and tetrahydropyrimidine mixing water gel are constituted；Described liposome accounts for composition weight
80%-99.8%, mean diameter is between 600-1600nm；Described restructuring epithelical cell growth factor accounts for composition weight
0.1-10.0%, its concentration is 100-2000mg/kg, and molecular weight is 5900-6500Da, and sedimentation coefficient is 1.20-1.30S, etc.
Electricity point is pH4.5-4.9, for lyophilized powder；Described tetrahydropyrimidine accounts for the 0.1-10.0% of composition quality ratio, and purity is
99%-100%, for powdery.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610814300.2A CN106267159A (en) | 2016-09-09 | 2016-09-09 | A kind of oral care composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610814300.2A CN106267159A (en) | 2016-09-09 | 2016-09-09 | A kind of oral care composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106267159A true CN106267159A (en) | 2017-01-04 |
Family
ID=57709910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610814300.2A Pending CN106267159A (en) | 2016-09-09 | 2016-09-09 | A kind of oral care composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106267159A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110946778A (en) * | 2019-12-19 | 2020-04-03 | 华熙生物科技股份有限公司 | Toothpaste with anti-inflammation and bacteriostasis functions |
| CN114214315A (en) * | 2021-11-19 | 2022-03-22 | 山东福瑞达生物科技有限公司 | RNA stabilizer containing tetrahydropyrimidine and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102210685A (en) * | 2011-04-29 | 2011-10-12 | 济南环肽医药科技有限公司 | Application of ectoine and derivatives thereof in preparing medicament for preventing and treating digestive tract diseases caused by chemotherapy medicaments |
| CN102753145A (en) * | 2010-02-10 | 2012-10-24 | 宝洁公司 | Liquid composition comprising a non-menthol cooling agent and a thickener for treating a respiratory symptom |
| CN103463627A (en) * | 2013-09-11 | 2013-12-25 | 拉芳家化股份有限公司 | Oral care composition containing heat-resistant superoxide dismutase and growth factors |
| CN103607998A (en) * | 2011-04-19 | 2014-02-26 | 马威苏德公司 | Method of preparation of chitin and active principles complexes and the so obtained complexes |
-
2016
- 2016-09-09 CN CN201610814300.2A patent/CN106267159A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102753145A (en) * | 2010-02-10 | 2012-10-24 | 宝洁公司 | Liquid composition comprising a non-menthol cooling agent and a thickener for treating a respiratory symptom |
| CN103607998A (en) * | 2011-04-19 | 2014-02-26 | 马威苏德公司 | Method of preparation of chitin and active principles complexes and the so obtained complexes |
| CN102210685A (en) * | 2011-04-29 | 2011-10-12 | 济南环肽医药科技有限公司 | Application of ectoine and derivatives thereof in preparing medicament for preventing and treating digestive tract diseases caused by chemotherapy medicaments |
| CN103463627A (en) * | 2013-09-11 | 2013-12-25 | 拉芳家化股份有限公司 | Oral care composition containing heat-resistant superoxide dismutase and growth factors |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110946778A (en) * | 2019-12-19 | 2020-04-03 | 华熙生物科技股份有限公司 | Toothpaste with anti-inflammation and bacteriostasis functions |
| CN114214315A (en) * | 2021-11-19 | 2022-03-22 | 山东福瑞达生物科技有限公司 | RNA stabilizer containing tetrahydropyrimidine and application thereof |
| CN114214315B (en) * | 2021-11-19 | 2022-08-30 | 山东福瑞达生物科技有限公司 | RNA stabilizer containing tetrahydropyrimidine and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Godin et al. | Ethosomes: new prospects in transdermal delivery | |
| US20070231377A1 (en) | Compositions for promoting hair growth | |
| KR20070072482A (en) | Organo-gel formulations for therapeutic applications | |
| CN102065851A (en) | Nanoemulsions for treating fungal, yeast and mold infections | |
| IL104283A (en) | Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate | |
| CN111166760A (en) | composition of beta-nicotinamide mononucleotide or precursor thereof, preparation method and application | |
| CN102871956A (en) | Propranolol hydrochloride gel for treating infant superficial hemangioma | |
| CN107375032B (en) | Composition for repairing skin barrier and preparation method thereof | |
| CN105848662A (en) | Tumoricidal and antimicrobial compositions and methods | |
| CN101283957B (en) | Enhanced hair growth composition and enhanced hair growth method | |
| DE10154579A1 (en) | Topical use of cytokines and chemokines for the treatment of viral or mycotic skin diseases or tumors | |
| CN106389139A (en) | Acne-removing, mark-eliminating and skin-protecting multifunctional preparation and preparation method thereof | |
| CN106267159A (en) | A kind of oral care composition | |
| BG62032B1 (en) | Antiviral active pharmaceutical emulsion of oil in water containing acyclovir or its salt or ester | |
| CN103463627B (en) | A kind of oral care composition containing heat-resistant superoxide dismutase and somatomedin | |
| CN105640793A (en) | Composition for preparing skin cream, skin cream prepared from composition and preparing method of skin cream | |
| KR101702648B1 (en) | A preservative for skin external application, and a cosmetic composition and a pharmaceutical composition comprising the same | |
| CN104107162B (en) | A kind of micro emulsion gels pharmaceutical composition and preparation method thereof | |
| CN110448525A (en) | A kind of external application Finasteride lipid nanometer preparation and preparation method thereof prevented hair loss with growth-promoting hair | |
| CN102247374B (en) | Application of tetrahydropyrimidin and derivative thereof in preparation of medicament for treating skin wound | |
| CN101711729B (en) | Skin care cosmetic containing liposome recombinant human growth hormone and preparation method thereof | |
| CN105899221A (en) | Dermatological composition based on algae and olive leaf extracts | |
| CN101596310A (en) | A kind of artificial substrate membrane emulsifying paste that is used for wound repair | |
| CN101132804A (en) | Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same | |
| US20120003323A1 (en) | Eye drops containing a deproteinized calf blood extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |
|
| RJ01 | Rejection of invention patent application after publication |